Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007.

Wang Z, Bhattacharyya T.

J Bone Miner Res. 2011 Mar;26(3):553-60. doi: 10.1002/jbmr.233.

2.

Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry.

Lee YK, Ha YC, Park C, Yoo JJ, Shin CS, Koo KH.

Osteoporos Int. 2013 Feb;24(2):707-11. doi: 10.1007/s00198-012-2016-8. Epub 2012 May 23.

PMID:
22618268
3.

Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.

Wang Z, Ward MM, Chan L, Bhattacharyya T.

Osteoporos Int. 2014 Aug;25(8):2109-16. doi: 10.1007/s00198-014-2738-x. Epub 2014 May 21.

4.

Trends in Media Reports, Oral Bisphosphonate Prescriptions, and Hip Fractures 1996-2012: An Ecological Analysis.

Jha S, Wang Z, Laucis N, Bhattacharyya T.

J Bone Miner Res. 2015 Dec;30(12):2179-87. doi: 10.1002/jbmr.2565. Epub 2015 Jul 14.

5.

Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women.

Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ, Laupacis A.

JAMA. 2011 Feb 23;305(8):783-9. doi: 10.1001/jama.2011.190.

PMID:
21343577
6.

Trends in hospital care for hip fractures.

Gehlbach SH, Avrunin JS, Puleo E.

Osteoporos Int. 2007 May;18(5):585-91. Epub 2006 Dec 5.

PMID:
17146592
7.

Epidemiology of proximal femoral fractures in South Korea.

Yoon BH, Lee YK, Kim SC, Kim SH, Ha YC, Koo KH.

Arch Osteoporos. 2013;8:157. doi: 10.1007/s11657-013-0157-9. Epub 2013 Oct 23.

PMID:
24150727
8.

Bisphosphonates and hip and nontraumatic subtrochanteric femoral fractures in the Veterans Health Administration.

Safford MM, Barasch A, Curtis JR, Outman R, Saag K.

J Clin Rheumatol. 2014 Oct;20(7):357-62. doi: 10.1097/RHU.0000000000000170.

PMID:
25275761
9.

Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene.

Vestergaard P, Schwartz F, Rejnmark L, Mosekilde L.

Osteoporos Int. 2011 Mar;22(3):993-1001. doi: 10.1007/s00198-010-1512-y. Epub 2010 Dec 17.

PMID:
21165600
10.

Subtrochanteric fractures in bisphosphonate-naive patients: results from the HORIZON-recurrent fracture trial.

Adachi JD, Lyles K, Boonen S, Colón-Emeric C, Hyldstrup L, Nordsletten L, Pieper C, Recknor C, Su G, Bucci-Rechtweg C, Magaziner J.

Calcif Tissue Int. 2011 Dec;89(6):427-33. doi: 10.1007/s00223-011-9543-8. Epub 2011 Oct 30.

11.

Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.

Pazianas M, Abrahamsen B, Wang Y, Russell RG.

Osteoporos Int. 2012 Dec;23(12):2873-84. doi: 10.1007/s00198-012-1952-7. Epub 2012 Mar 20.

PMID:
22431012
12.

Subtrochanteric/femoral shaft versus hip fractures: incidences and identification of risk factors.

Maravic M, Ostertag A, Cohen-Solal M.

J Bone Miner Res. 2012 Jan;27(1):130-7. doi: 10.1002/jbmr.517.

13.

Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis.

Abrahamsen B, Eiken P, Eastell R.

J Clin Endocrinol Metab. 2010 Dec;95(12):5258-65. doi: 10.1210/jc.2010-1571. Epub 2010 Sep 15.

14.

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC; Fracture Intervention Trial Steering Committee.; HORIZON Pivotal Fracture Trial Steering Committee..

N Engl J Med. 2010 May 13;362(19):1761-71. doi: 10.1056/NEJMoa1001086. Epub 2010 Mar 24.

15.

Incidence and mortality of hip fractures in the United States.

Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB.

JAMA. 2009 Oct 14;302(14):1573-9. doi: 10.1001/jama.2009.1462.

16.

Bisphosphonate use and atypical fractures of the femoral shaft.

Schilcher J, Michaëlsson K, Aspenberg P.

N Engl J Med. 2011 May 5;364(18):1728-37. doi: 10.1056/NEJMoa1010650. Erratum in: N Engl J Med. 2011 Oct 20;365(16):1551. N Engl J Med. 2012 Aug 9;367(6):582.

17.

Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis.

Gedmintas L, Solomon DH, Kim SC.

J Bone Miner Res. 2013 Aug;28(8):1729-37. doi: 10.1002/jbmr.1893. Review.

18.

The impact of subtrochanteric fracture criteria on hip fracture classification.

Huang SY, Grimsrud CD, Provus J, Hararah M, Chandra M, Ettinger B, Lo JC.

Osteoporos Int. 2012 Feb;23(2):743-50. doi: 10.1007/s00198-011-1622-1. Epub 2011 May 12.

PMID:
21562878
19.

The impact of decreasing U.S. hip fracture rates on future hip fracture estimates.

Stevens JA, Rudd RA.

Osteoporos Int. 2013 Oct;24(10):2725-8. doi: 10.1007/s00198-013-2375-9. Epub 2013 Apr 30.

20.

Long-term bisphosphonate usage and subtrochanteric insufficiency fractures: a cause for concern?

Yoon RS, Hwang JS, Beebe KS.

J Bone Joint Surg Br. 2011 Oct;93(10):1289-95. doi: 10.1302/0301-620X.93B10.26924. Review.

PMID:
21969423

Supplemental Content

Support Center